AstraZeneca, Ardelyx Target Kidney Disease | Chemical & Engineering News
Volume 90 Issue 42 | p. 19 | Concentrates
Issue Date: October 15, 2012

AstraZeneca, Ardelyx Target Kidney Disease

Department: Business
Keywords: pharmaceuticals, kidney disease, NHE3 inhibitor

AstraZeneca will pay $35 million up front for access to Ardelyx’ inhibitors of NHE3, a protein needed for the absorption of sodium in the intestines. The deal includes RDX5791, an NHE3 blocker that has completed a midstage study as an irritable bowel syndrome treatment and is poised for Phase II studies to treat kidney disease. Fremont, Calif.-based Ardelyx could reap another $237.5 million in milestones as compounds reach the market. AstraZeneca is taking on remaining development costs for RDX5791.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment